August 16, 2017

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Compared to ALK rearrangements, ROS1 rearrangements are associated with lower rates of extrathoracic metastases, including fewer brain metastases, at initial metastatic diagnosis. ROS1 resistance mutations, particularly G2032R, appear to be the predominant mechanism of resistance to crizotinib, underscoring the need to develop novel ROS1 inhibitors with activity against these resistant mutants.

Demander à l'IA

Bookmark

Cite This Study

Gainor et al. (Wed,) studied this question.

synapsesocial.com/papers/69d72c193f906f6a06bef965 https://doi.org/https://doi.org/10.1200/po.17.00063

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer2018 · 246 citations
2Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer2007 · 2,307 citations
3Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations — Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R2016 · 7 citations
4Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer2014 · 1,995 citations
5Activation of RAS family members confers resistance to ROS1 targeting drugs2014 · 81 citations

Demander à l'IA

Bookmark